Abstract: A method and system for controlling and adjusting light in interstitial photodynamic light therapy (IPDT) in a subject is disclosed. More particularly, a method for controlling the light in interstitial tumor photodynamic light therapy is described using a calculation method for determination of status of tissue during the PDT treatment. The status is used in a feedback loop to control the continued PDT treatment. Methods are disclosed that constitute pre-treatment and realtime dosimetry modules for IPDT on the whole prostate glandular tissue. The method includes reconstruction of the target geometry, optimization of source fiber positions within this geometry, monitoring of the light attenuation during the treatment procedure and updating individual fiber irradiation times to take into account any variation in tissue light transmission.

Abstract: A method and system for controlling and adjusting light in interstitial photodynamic light therapy (IPDT) in a subject is disclosed. More particularly, a method for controlling the light in interstitial tumor photodynamic light therapy is described using calculation method for determination of status of tissue during the PDT treatment. The status is used in a feedback loop to control the continued PDT treatment. Methods are disclosed that constitute pre-treatment and realtime dosimetry modules for IPDT on the whole prostate glandular tissue. The method includes reconstruction of the target geometry, optimization of source fiber positions within this geometry, monitoring of the light attenuation during the treatment procedure and updating individual fiber irradiation times to take into account any variation in tissue light transmission.

Abstract: A system and method for therapy and diagnosis of a human or animal. At least one coupling element for coupling of radiation couples radiation from at least a first radiation source to a tumor site and/or from said second radiation source to said site and/or from said site to a detector. The coupling elements are combinations of at least one translatory distributor, at least one rotary distributor, and at least one operation mode selector means for directing either said therapeutic radiation or said diagnostic radiation to said site through said at least one first radiation conductor. The system may be used for interactive interstitial photodynamic tumor therapy. The system and method according to the invention combines the advantages of purely mechanical and purely non-mechanical solutions in a new and synergetic way.

Abstract: A system and method for therapy and diagnosis of a human or animal. At least one coupling element for coupling of radiation couples radiation from at least a first radiation source to a tumour site and/or from said second radiation source to said site and/or from said site to a detector. The coupling elements are combinations of at least one translatory distributor, at least one rotary distributor, and at least one operation mode selector means for directing either said therapeutic radiation or said diagnostic radiation to said site through said at least one first radiation conductor. The system may be used for interactive interstitial photodynamic tumour therapy. The system and method according to the invention combines the advantages of purely mechanical and purely non-mechanical solutions in a new and synergetic way.

Abstract: Aerosol formulations suitable for use in pressurised metered dose inhalers comprise a hydrofluoroalkane propellant, an medicament for inhalation and a surfactant which is a a C8–C16 fatty acid or salt thereof, a bile salt, a phospholipid, or an alkyl saccharide.

Abstract: The present invention relates to compositions and methods for pulmonary administration of full-length parathyroid hormone to mammalian hosts for the treatment of osteoporosis. Thus there is provided a therapeutic preparation comprising a human full-length parathyroid hormone, or homologues thereof, in the form of a dry powder suitable for inhalation in which at least 50% of said dry powder consists of (a) particles having a diameter of up to 10 microns; or (b) agglomerates, of such particles.

Abstract: A pharmaceutical aerosol formulation comprising (a) a HFA propellant; (b) a pharmaceutically active polypeptide dispersible in the propellant; and (c) a surfactant which is a C8-C16 fatty acid or salt thereof, a bile salt, a phospholipid, or an alkyl saccharide, which surfactant enhances the systemic absorption of the polypeptide in the lower respiratory tract. The invention also relates to methods of manufacturing such formulations and the use of such formulations in treating patients.

Abstract: The present invention relates to compositions and methods for pulmonary administration of full-length parathyroid hormone to mammalian hosts for the treatment of osteoporosis. Thus there is provided a therapeutic preparation comprising a human full-length parathyroid hormone, or homologues thereof, in the form of a dry powder suitable for inhalation in which at least 50% of said dry powder consists of (a) particles having a diameter of up to 10 microns; or (b) agglomerates of such particles.

Abstract: The present invention relates to compositions and methods for pulmonary administration of full-length parathyroid hormone to mamnmalian hosts for the treatment of osteoporosis. Thus there is provided a therapeutic preparation comprising a human full-length parathyroid hormone, or homologues thereof, in the form of a dry powder suitable for inhalation in which at least 50% of said dry powder consists of (a) particles having a diameter of up to 10 microns; or (b) agglomerates of such particles.

Abstract: A powder formulation for the administration of medically useful polypeptides, comprising a medically useful polypeptide with melezitose as diluent.